Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 9Myeloid 3Gastrointestinal 1CNS 1

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Cholangiocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 76Temozolomide 73Specimen Handling 49Radiotherapy 46Radiosurgery 34Cyclophosphamide 28Bevacizumab 26Radiation 25pembrolizumab 24Biopsy 23Nivolumab 21Carboplatin 16fludarabine 14X-Rays 13Ipilimumab 13Surgical Procedures, Operative 12Lomustine 12Irinotecan 12Vincristine 11Topotecan 11Cisplatin 11Blood Specimen Collection 11dinutuximab 10trametinib 9abemaciclib 9AZD 6244 9lutetium Lu 177 dotatate 8Immunoglobulin G 8Etoposide 8Doxorubicin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
olutasidenib × CNS × 90 days × Clear all
NCT07486713 2026-03-20

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡